Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$5.19 USD
-0.20 (-3.71%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $5.19 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Lyra Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 1 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2 | 1 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 69 | 58 | 44 | 22 | 17 |
Income After Depreciation & Amortization | -67 | -56 | -44 | -22 | -17 |
Non-Operating Income | 5 | 1 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -63 | -55 | -44 | -22 | -16 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -63 | -55 | -44 | -22 | -16 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -63 | -55 | -44 | -22 | -16 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -70 | -56 | -43 | -22 | -16 |
Depreciation & Amortization (Cash Flow) | -3 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -67 | -56 | -44 | -22 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 49.80 | 30.24 | 12.99 | 8.59 | NA |
Diluted EPS Before Non-Recurring Items | -1.23 | -1.83 | -3.35 | -2.59 | NA |
Diluted Net EPS (GAAP) | -1.26 | -1.83 | -3.35 | -2.59 | NA |
Fiscal Year end for Lyra Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.15 | 0.54 | 0.46 | 0.41 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.15 | 0.54 | 0.46 | 0.41 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 16.63 | 17.37 | 16.96 | 17.73 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -16.48 | -16.83 | -16.50 | -17.32 |
Non-Operating Income | NA | 1.34 | 1.19 | 0.90 | 1.07 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -15.14 | -15.64 | -15.61 | -16.24 |
Income Taxes | NA | 0.02 | 0.02 | 0.01 | 0.01 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -15.16 | -15.65 | -15.62 | -16.26 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -15.16 | -15.65 | -15.62 | -16.26 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 67.96 | 56.95 | 43.68 | 36.83 |
Diluted EPS Before Non-Recurring Items | NA | -0.22 | -0.27 | -0.33 | -0.44 |
Diluted Net EPS (GAAP) | NA | -0.19 | -0.27 | -0.36 | -0.44 |